Aclarion Conducts CLUE Trial to Measure Impact of Nociscan's AI on Surgical Decisions

Aclarion ACON, a company listed on NASDAQ under the tickers ACONW for warrants and ACON for common stock, has launched an ambitious Clinical Utility and Economic (CLUE) Trial. The aim is to investigate the extent to which the company's AI-generated biomarker data, Nociscan, influences surgeons' treatment plans. The study will be particularly focused on collecting data in a real-world setting, enhancing Aclarion’s existing clinical evidence.

Understanding the CLUE Trial

The CLUE trial is designed to capture data on how surgical decisions change after surgeons are provided with information from Nociscan. Prior to using the AI tool, participating surgeons will outline their intended treatment strategies for specific cases. They will then report on any changes to their plans after receiving insights from the Nociscan system. It is expected that this AI-driven data will offer a new dimension to surgical planning, potentially leading to more informed decision-making and improved patient outcomes.

Broader Implications of the Study

The trial will be conducted across multiple facilities with several physicians participating in the coming months. The addition of practical, real-life data will complement the growing body of evidence that supports the use of AI in clinical settings. The results from the CLUE trial could have significant implications not only for Aclarion’s market position but also for the broader medical field, offering insights into the practical benefits of technology in surgical planning.

For investors and stakeholders in Aclarion ACON, the trial represents an important milestone that could shape the company’s future prospects. The integration of AI tools like Nociscan in surgical planning potentially points to a future where technology and healthcare are even more intricately connected.

Aclarion, Nociscan, CLUE